DOCSLIB.ORG

2862.Full-Text.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2862.Full-Text.Pdf Published OnlineFirst September 27, 2017; DOI: 10.1158/1535-7163.MCT-17-0130 Cancer Biology and Translational Studies Molecular Cancer Therapeutics CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma Chang-Xin Shi1, K. Martin Kortum€ 1,2, Yuan Xiao Zhu1, Laura A. Bruins1, Patrick Jedlowski1, Patrick G. Votruba3, Moulun Luo4, Robert A. Stewart1, Jonathan Ahmann1, Esteban Braggio1, and A. Keith Stewart1,5 Abstract Bortezomib is highly effective in the treatment of multiple validation. Of these 20 targets, the proteasome regulatory myeloma; however, emergent drug resistance is common. Con- subunit PSMC6 was the only gene validated to reproducibly sequently, we employed CRISPR targeting 19,052 human genes confer bortezomib resistance. We confirmed that inhibition of to identify unbiased targets that contribute to bortezomib chymotrypsin-like proteasome activity by bortezomib was sig- resistance. Specifically, we engineered an RPMI8226 multiple nificantly reduced in cells lacking PSMC6. We individually myeloma cell line to express Cas9 infected by lentiviral vector investigated other members of the PSMC group (PSMC1 to CRISPR library and cultured derived cells in doses of bortezo- 5) and found that deficiency in each of those subunits also mib lethal to parental cells. Sequencing was performed on imparts bortezomib resistance. We found 36 mutations in 19S surviving cells to identify inactivated genes responsible for drug proteasome subunits out of 895 patients in the IA10 release resistance. From two independent whole-genome screens, we of the CoMMpass study (https://themmrf.org). Our findings selected 31 candidate genes and constructed a second CRISPR demonstrate that the PSMC6 subunit is the most prominent sgRNA library, specifically targeting each of these 31 genes with target required for bortezomib sensitivity in multiple myeloma four sgRNAs. After secondary screening for bortezomib resis- cells and should be examined in drug-refractory populations. tance, the top 20 "resistance" genes were selected for individual Mol Cancer Ther; 16(12); 2862–70. Ó2017 AACR. Introduction have been identified frequently in multiple myeloma cell line but are not found in newly diagnosed patients (17, 18), while XBP1 Multiple myeloma is a plasma cell malignancy, which has seen mutations have also been seen but are also found in less than 1% significant improvements in outcomes following the introduction of newly diagnosed multiple myeloma cases. Indeed, the muta- of proteasome inhibitors (PI), specifically bortezomib, carfilzo- tion prevalence of these genes combined is only 2% in supposedly mib, and ixazomib into routine clinical practice (1–6). PIs used in PI-refractory patients (19). XBP1 knockdown experiments have combination with other compounds achieve initial response in shown correlation with bortezomib resistance (14, 20). Recently, nearly 90% to 100% of patients (7). Despite the high initial Acosta-Alvear and colleagues reported an shRNA screening and response rates, almost all patients develop drug resistance over found that genetic depletion of the vast majority of the 19S time and eventually becoming refractory to PIs. The underlying proteasomal regulator subunits, including PSMC1 and 6, con- mechanisms of such PI resistance are still incompletely under- ferred a marked resistance to PIs (21). In a separate study, Tsvetkov stood (8). The genes and pathways most commonly associated and colleagues using gene-trap screening identified that with bortezomib resistance are PSMB5 (9–13), the ERN1–XBP1 compromising the 19S proteasome including PSMC2 - 6 pro- pathway (14, 15) as well as the IGF-1 axis (16). PSBM5 mutations tected cells from proteasome inhibitors (22). Sheffer and collea- gues (23) using CRISPR technology also identified loss of PSMC6 as inducing resistance, although to date, results are only published 1Department of Hematology, Mayo Clinic in Arizona, Scottsdale, Arizona. in abstract form. 2Department of Hematology, University Hospital Wurzburg,€ Wurzburg,€ Ger- CRISPR-Cas9 knockout is a precise and efficient genome-edit- many. 3Bioinformatics Systems, Mayo Clinic in Arizona, Scottsdale, Arizona. ing technology (24, 25). This simple gene-engineering tool con- 4Mayo/ASU Center for Metabolic and Vascular Biology, Arizona State University, 5 sists of a 20-base pair single-guide RNA (sgRNA) and a Cas9 Scottsdale, Arizona. Center for Individualized Medicine, Mayo Clinic, Rochester, protein, which can specifically recognize and cut the sgRNA- Minnesota. binding region (24). Recently, a genome-scale CRISPR-Cas9 Note: Supplementary data for this article are available at Molecular Cancer library was developed (26, 27) including 19,052 human genes, Therapeutics Online (http://mct.aacrjournals.org/). each gene being targeted with six sgRNAs. We used this genome- Corresponding Author: A. Keith Stewart, Mayo Clinic in Arizona, 13400 East wide library to identify genes that are potentially associated Shea Blvd, Scottsdale, AZ 85259. Phone: 507-284-5511; Fax: 507-293-2379; with bortezomib resistance. Our screening identified absence of E-mail: [email protected] the proteasome-regulatory subunit PSMC6 as the gene most doi: 10.1158/1535-7163.MCT-17-0130 consistently conferring bortezomib resistance in human multiple Ó2017 American Association for Cancer Research. myeloma cells. 2862 Mol Cancer Ther; 16(12) December 2017 Downloaded from mct.aacrjournals.org on October 1, 2021. © 2017 American Association for Cancer Research. Published OnlineFirst September 27, 2017; DOI: 10.1158/1535-7163.MCT-17-0130 PSMC6 Deficiency Causing Bortezomib Resistance in MM Materials and Methods hour later, 3 mL of fresh medium was added. Next morning, the medium was changed to 6 mL fresh medium. Cell lines and plasmids Human multiple myeloma cell lines RPMI8226, FR4, JJN3, CRISPR sgRNA screening KMS11, KMS18, MM1.R, OPM2, and U266 were maintained in RPMI8226Cas9 cells were infected with the CRISPR library. The m RPMI1640 with 5% FBS, 100 U/mL penicillin and 100 g/mL infected cells were treated with bortezomib at 7 nmol/L for 7 days streptomycin. All multiple myeloma cells were from Dr. Leif (changed medium with 7 nmol/L bortezomib at days 2 and 4). Bergsagel's laboratory. These cells were tested negative for myco- Residual cells surviving bortezomib treatment were expanded fi plasma and validated by ngerprinting developed by Dr. Bergsa- over 15 days without bortezomib treatment and then subjected gel's laboratory (unpublished data). All experiments were per- to DNA sequencing formed on multiple myeloma cells less than 20 passages after thawing from liquid nitrogen. Plasmids pCDHpuroCr expressing DNA sequencing and data analysis selection marker puromycin and pCDHgfpCr expressing a green We screened the abundance of sgRNA targeting the approxi- fl uorescent protein selection marker (GFP) for cloning sgRNAs mately 19K genes in cells showing resistance to bortezomib by were derived from pCDH-CMV-MCS-EF1-Puro and pCDH-CMV- next-generation sequencing (Ion Torrent PGM, Thermo Fisher MCS-EF1-copGFP (SBI), respectively, by cloning the sgRNA Scientific). An in-house algorithm was used to clean the gene- expression cassette from plasmid lentiGuide-Puro (Addgene specific sgRNA by eliminating the surrounding adapters #52963; ref. 28). Plasmid pCDHBlastCas9HA was derived from sequences. A script written in the Perl programming language lentiCas9-blast (#52962; ref. 28) by cloning Cas9 gene (Flag tag was used to identify all instances of the "tag" sequence was replaced with HA tag) into pCDHBlast under the control of AAAGGACGAAACACC? that occur in the fasta files. The "?" can CMV promoter, which was constructed by Shi and colleagues denote A, C, G, or T. The script also captures the next "target" (C.X. Shi; unpublished observations). sequence of 20 nucleotides downstream from the tag. The targets are stored in a hash table, which counts the frequency with which Small molecules each target appears adjacent to the tag. The gene-specific sgRNA Tunicamycin was from Abcam (cat. Ab120296) and its struc- were quantified, and the 100 most abundant hits were subse- ture was published by Takatsuki and colleagues (29). Stauros- quently blasted against the human genome. porine was from ApexBio (cat. A8192) and its structure was published by Furusaki and colleagues (30, 31). Bortezomib was Proteasome chymotrypsin-like activity, caspase-3 and 7 activity from LC Laboratories (cat. B-1408). Carfilzomib was from MCE assay, and 26S proteasome assay Medchem Express (cat. HY10455). Dexamethasone (cat. D4902- Proteasome chymotrypsin-like activity was measured by cell- 25MG) and melphalan (cat M2011-100MG) were from Sigma. based assay, which was performed according to the manufac- fl Utilization of sgRNA turer's description (cat no. G8660, Promega). Brie y, 2,000 cells The GeCKO V2 library (Addgene #100000049; ref. 28) was were plated into 384-well plates. Cells were treated with different expanded by transforming the library into DH10B cells by elec- concentration (3, 4, 5, 6, 7, 8, and 9 nmol/L) of bortezomib for trophoresis with a total of 2.5 Â 107 clones produced. A sgRNA 24 hours. Then, proteasome-Glo reagent was added into the cells. library for the second round screening was created by cloning Luciferase activity was assayed by luciferase reader Cytation 3 sgRNAs synthesized by IDT technology individually, mixed man- imaging reader. Caspase-3 and 7 activity assay was similar to ually, and finally cloned into the vector pCDHgfpCr.
Load more

Recommended publications
  • The Potential Role of Necroptosis in Clinical Diseases (Review)
    INTERNATIONAL JOURNAL OF MOleCular meDICine 47: 89, 2021 The potential role of necroptosis in clinical diseases (Review) WENLI DAI1*, JIN CHENG1*, XI LENG2, XIAOQING HU1 and YINGFANG AO1 1Institute of Sports Medicine, Beijing Key Laboratory of Sports Injuries, Peking University Third Hospital, Beijing 100191; 2Medical Imaging Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510405, P.R. China Received November 19, 2020; Accepted March 8, 2021 DOI: 10.3892/ijmm.2021.4922 Abstract. As an important type of programmed cell death in 1. Introduction addition to apoptosis, necroptosis occurs in a variety of patho‑ physiological processes, including infections, liver diseases, Necroptosis, an emerging field closely related to apoptosis, is a kidney injury, neurodegenerative diseases, cardiovascular non‑caspase‑dependent cell death that has been implicated in diseases, and human tumors. It can be triggered by a variety the pathological processes of various diseases. It is regulated of factors, such as tumor necrosis factor receptor and Toll‑like by various genes that cause regular and ordered cell death. receptor families, intracellular DNA and RNA sensors, and Through activating specific death signaling pathways, it shares interferon, and is mainly mediated by receptor‑interacting typical characteristics of necrosis, including loss of metabolic protein kinase 1 (RIP1), RIP3, and mixed lineage kinase function and subcellular changes (1,2). Receptor‑interacting domain‑like protein. A better understanding of the mechanism protein kinase 1 (RIP1) was the first signaling molecule of necroptosis may be useful in the development of novel drugs identified in the necrosome (3). RIP1 and RIP3 interact for necroptosis‑related diseases.
    [Show full text]
  • Uncovering the Signaling Landscape Controlling Breast Cancer Cell Migration Identifies Novel Metastasis Driver Genes
    ARTICLE https://doi.org/10.1038/s41467-019-11020-3 OPEN Uncovering the signaling landscape controlling breast cancer cell migration identifies novel metastasis driver genes Esmee Koedoot1,4, Michiel Fokkelman 1,4, Vasiliki-Maria Rogkoti1,4, Marcel Smid2, Iris van de Sandt1, Hans de Bont1, Chantal Pont1, Janna E. Klip1, Steven Wink 1, Mieke A. Timmermans2, Erik A.C. Wiemer2, Peter Stoilov3, John A. Foekens2, Sylvia E. Le Dévédec 1, John W.M. Martens 2 & Bob van de Water1 1234567890():,; Ttriple-negative breast cancer (TNBC) is an aggressive and highly metastatic breast cancer subtype. Enhanced TNBC cell motility is a prerequisite of TNBC cell dissemination. Here, we apply an imaging-based RNAi phenotypic cell migration screen using two highly motile TNBC cell lines (Hs578T and MDA-MB-231) to provide a repository of signaling determinants that functionally drive TNBC cell motility. We have screened ~4,200 target genes individually and discovered 133 and 113 migratory modulators of Hs578T and MDA-MB-231, respectively, which are linked to signaling networks predictive for breast cancer progression. The splicing factors PRPF4B and BUD31 and the transcription factor BPTF are essential for cancer cell migration, amplified in human primary breast tumors and associated with metastasis-free survival. Depletion of PRPF4B, BUD31 and BPTF causes primarily down regulation of genes involved in focal adhesion and ECM-interaction pathways. PRPF4B is essential for TNBC metastasis formation in vivo, making PRPF4B a candidate for further drug development. 1 Division of Drug Discovery and Safety, LACDR, Leiden University, Einsteinweg 55, Leiden 2333 CC, Netherlands. 2 Department of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam 3008 AE, Netherlands.
    [Show full text]
  • Nuclear and Mitochondrial Genome Defects in Autisms
    UC Irvine UC Irvine Previously Published Works Title Nuclear and mitochondrial genome defects in autisms. Permalink https://escholarship.org/uc/item/8vq3278q Journal Annals of the New York Academy of Sciences, 1151(1) ISSN 0077-8923 Authors Smith, Moyra Spence, M Anne Flodman, Pamela Publication Date 2009 DOI 10.1111/j.1749-6632.2008.03571.x License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California THE YEAR IN HUMAN AND MEDICAL GENETICS 2009 Nuclear and Mitochondrial Genome Defects in Autisms Moyra Smith, M. Anne Spence, and Pamela Flodman Department of Pediatrics, University of California, Irvine, California In this review we will evaluate evidence that altered gene dosage and structure im- pacts neurodevelopment and neural connectivity through deleterious effects on synap- tic structure and function, and evidence that the latter are key contributors to the risk for autism. We will review information on alterations of structure of mitochondrial DNA and abnormal mitochondrial function in autism and indications that interactions of the nuclear and mitochondrial genomes may play a role in autism pathogenesis. In a final section we will present data derived using Affymetrixtm SNP 6.0 microar- ray analysis of DNA of a number of subjects and parents recruited to our autism spectrum disorders project. We include data on two sets of monozygotic twins. Col- lectively these data provide additional evidence of nuclear and mitochondrial genome imbalance in autism and evidence of specific candidate genes in autism. We present data on dosage changes in genes that map on the X chromosomes and the Y chro- mosome.
    [Show full text]
  • Genetic Variations in the PSMA6 and PSMC6 Proteasome Genes Are Associated with Multiple Sclerosis and Response to Interferon‑Β Therapy in Latvians
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 21: 478, 2021 Genetic variations in the PSMA6 and PSMC6 proteasome genes are associated with multiple sclerosis and response to interferon‑β therapy in Latvians NATALIA PARAMONOVA1, JOLANTA KALNINA1, KRISTINE DOKANE1, KRISTINE DISLERE1, ILVA TRAPINA1, TATJANA SJAKSTE1 and NIKOLAJS SJAKSTE1,2 1Genomics and Bioinformatics, Institute of Biology of The University of Latvia; 2Department of Medical Biochemistry of The University of Latvia, LV‑1004 Riga, Latvia Received July 8, 2020; Accepted December 8, 2020 DOI: 10.3892/etm.2021.9909 Abstract. Several polymorphisms in genes related to the Introduction ubiquitin‑proteasome system exhibit an association with pathogenesis and prognosis of various human autoimmune Multiple sclerosis (MS) is a lifelong demyelinating disease of diseases. Our previous study reported the association the central nervous system. The clinical onset of MS tends to between multiple sclerosis (MS) and the PSMA3‑rs2348071 be between the second and fourth decade of life. Similarly to polymorphism in the Latvian population. The current study other autoimmune diseases, women are affected 3‑4 times more aimed to evaluate the PSMA6 and PSMC6 genetic variations, frequently than men (1). About 10% of MS patients experience their interaction between each other and with the rs2348071, a primary progressive MS form characterized by the progres‑ on the susceptibility to MS risk and response to therapy in sion of neurological disability from the onset. In about 90% the Latvian population. PSMA6‑rs2277460, ‑rs1048990 and of MS patients, the disease undergoes the relapse‑remitting PSMC6‑rs2295826, ‑rs2295827 were genotyped in the MS MS course (RRMS); in most of these patients, the condition case/control study and analysed in terms of genotype‑protein acquires secondary progressive course (SPMS) (2).
    [Show full text]
  • A Minimal Set of Internal Control Genes for Gene Expression Studies in Head
    bioRxiv preprint doi: https://doi.org/10.1101/108381; this version posted February 14, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 A minimal set of internal control genes for gene expression studies in head 2 and neck squamous cell carcinoma. 1 1 1 2 3 Vinayak Palve , Manisha Pareek , Neeraja M Krishnan , Gangotri Siddappa , 2 2 1,3* 4 Amritha Suresh , Moni Abraham Kuriakose and Binay Panda 5 1 6 Ganit Labs, Bio-IT Centre, Institute of Bioinformatics and Applied Biotechnology, 7 Bangalore 560100 2 8 Mazumdar Shaw Cancer Centre and Mazumdar Shaw Centre for Translational 9 Research, Bangalore 560096 3 10 Strand Life Sciences, Bangalore 560024 11 * Corresponding author: [email protected] 12 13 Abstract: 14 Background: Selection of the right reference gene(s) is crucial in the analysis and 15 interpretation of gene expression data. In head and neck cancer, studies evaluating 16 the efficacy of internal reference genes are rare. Here, we present data for a minimal 17 set of candidates as internal control genes for gene expression studies in head and 18 neck cancer. 19 Methods: We analyzed data from multiple sources (in house whole-genome gene 20 expression microarrays, n=21; TCGA RNA-seq, n=42, and published gene 21 expression studies in head and neck tumors from literature) to come up with a set of 22 genes (discovery set) for their stable expression across tumor and normal tissues.
    [Show full text]
  • Selective Androgen Receptor Modulators (Sarms) And
    (19) TZZ ¥6B_T (11) EP 2 222 636 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 207/08 (2006.01) C07D 207/09 (2006.01) 10.04.2013 Bulletin 2013/15 C07D 498/04 (2006.01) A61K 31/402 (2006.01) A61P 5/26 (2006.01) (21) Application number: 08865188.0 (86) International application number: (22) Date of filing: 12.12.2008 PCT/US2008/013657 (87) International publication number: WO 2009/082437 (02.07.2009 Gazette 2009/27) (54) SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF SELEKTIVE ANDROGENREZEPTORMODULATOREN (SARMS) UND IHRE VERWENDUNG MODULATEURS SÉLECTIFS DU RÉCEPTEUR ANDROGÈNE (SARM) ET LEURS UTILISATIONS (84) Designated Contracting States: (74) Representative: Baldock, Sharon Claire AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Boult Wade Tennant HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT Verulam Gardens RO SE SI SK TR 70 Gray’s Inn Road Designated Extension States: London WC1X 8BT (GB) AL BA MK RS (56) References cited: (30) Priority: 21.12.2007 US 8731 P WO-A-02/068427 WO-A-03/090672 WO-A-2005/090282 WO-A-2006/124447 (43) Date of publication of application: WO-A-2007/015567 01.09.2010 Bulletin 2010/35 • HIGUCHI ET AL: "Potent, nonsteroidal selective (60) Divisional application: androgen receptor modulators (SARMs) based 12168231.4 / 2 489 656 on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones" BIOORGANIC & MEDICINAL CHEMISTRY (73) Proprietor: Ligand Pharmaceuticals Inc.
    [Show full text]
  • Protein Expression Analysis of an in Vitro Murine Model of Prostate Cancer Progression: Towards Identification of High-Potential Therapeutic Targets
    Journal of Personalized Medicine Article Protein Expression Analysis of an In Vitro Murine Model of Prostate Cancer Progression: Towards Identification of High-Potential Therapeutic Targets Hisham F. Bahmad 1,2,3 , Wenjing Peng 4, Rui Zhu 4, Farah Ballout 1, Alissar Monzer 1, 1,5 6, , 1, , 4, , Mohamad K. Elajami , Firas Kobeissy * y , Wassim Abou-Kheir * y and Yehia Mechref * y 1 Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut 1107-2020, Lebanon; [email protected] (H.F.B.); [email protected] (F.B.); [email protected] (A.M.); [email protected] (M.K.E.) 2 Arkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, FL 33140, USA 3 Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA 4 Department of Chemistry and Biochemistry, Texas Tech University, Lubbock, TX 79409, USA; [email protected] (W.P.); [email protected] (R.Z.) 5 Department of Internal Medicine, Mount Sinai Medical Center, Miami Beach, FL 33140, USA 6 Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American University of Beirut, Beirut 1107-2020, Lebanon * Correspondence: [email protected] (F.K.); [email protected] (W.A.-K.); [email protected] (Y.M.); Tel.: +961-1-350000 (ext. 4805) (F.K.); +961-1-350000 (ext. 4778) (W.A.K.); +1-806-834-8246 (Y.M.); Fax: +1-806-742-1289 (Y.M.); 961-1-744464 (W.A.K.) These authors have contributed equally to this work as joint senior authors.
    [Show full text]
  • NPI-0052 and Γ-Radiation Induce a Synergistic Apoptotic Effect In
    Frisira et al. Cell Death and Disease (2019) 10:785 https://doi.org/10.1038/s41419-019-2026-y Cell Death & Disease ARTICLE Open Access NPI-0052 and γ-radiation induce a synergistic apoptoticeffectinmedulloblastoma Eleni Frisira1, Fatima Rashid1,SwastinaNathVarma2,SaraBadodi1, Valentine Ayodele Benjamin-Ombo1, David Michod 2 and Maria Victoria Niklison-Chirou 1 Abstract Medulloblastoma (MB) is the most common malignant solid paediatric brain tumour. The standard treatment for MB is surgical resection of the tumour, radiation and chemotherapy. This therapy is associated with high morbidity and adverse side effects. Hence, more targeted and less toxic therapies are vitally needed to improve the quality of life of survivors. NPI-0052 is a novel proteasome inhibitor that irreversibly binds the 20S proteasome subunit. This compound has anti-tumour activity in metastatic solid tumours, glioblastoma and multiple myeloma with a good safety profile. Importantly, NPI-0052 has a lipophilic structure and can penetrate the blood–brain barrier, making it a suitable treatment for brain tumours. In the present study, we performed an in silico gene expression analysis to evaluate the proteasome subunit expression in MB. To evaluate the anticancer activity of NPI-0052, we used a range of MB patient- derived MB cells and cell lines. The synergistic cell death of NPI-0052 with γ-radiation was evaluated in tumour organoids derived from patient-derived MB cells. We show that high expression of proteasome subunits is a poor prognostic factor for MB patients. Also, our preclinical work demonstrated that NPI-0052 can inhibit proteasome activity and activate apoptosis in MB cells. Moreover, we observe that NPI-0052 has a synergistic apoptotic effect with γ-radiation, a component of the current MB therapy.
    [Show full text]
  • Role of Phytochemicals in Colon Cancer Prevention: a Nutrigenomics Approach
    Role of phytochemicals in colon cancer prevention: a nutrigenomics approach Marjan J van Erk Promotor: Prof. Dr. P.J. van Bladeren Hoogleraar in de Toxicokinetiek en Biotransformatie Wageningen Universiteit Co-promotoren: Dr. Ir. J.M.M.J.G. Aarts Universitair Docent, Sectie Toxicologie Wageningen Universiteit Dr. Ir. B. van Ommen Senior Research Fellow Nutritional Systems Biology TNO Voeding, Zeist Promotiecommissie: Prof. Dr. P. Dolara University of Florence, Italy Prof. Dr. J.A.M. Leunissen Wageningen Universiteit Prof. Dr. J.C. Mathers University of Newcastle, United Kingdom Prof. Dr. M. Müller Wageningen Universiteit Dit onderzoek is uitgevoerd binnen de onderzoekschool VLAG Role of phytochemicals in colon cancer prevention: a nutrigenomics approach Marjan Jolanda van Erk Proefschrift ter verkrijging van graad van doctor op gezag van de rector magnificus van Wageningen Universiteit, Prof.Dr.Ir. L. Speelman, in het openbaar te verdedigen op vrijdag 1 oktober 2004 des namiddags te vier uur in de Aula Title Role of phytochemicals in colon cancer prevention: a nutrigenomics approach Author Marjan Jolanda van Erk Thesis Wageningen University, Wageningen, the Netherlands (2004) with abstract, with references, with summary in Dutch ISBN 90-8504-085-X ABSTRACT Role of phytochemicals in colon cancer prevention: a nutrigenomics approach Specific food compounds, especially from fruits and vegetables, may protect against development of colon cancer. In this thesis effects and mechanisms of various phytochemicals in relation to colon cancer prevention were studied through application of large-scale gene expression profiling. Expression measurement of thousands of genes can yield a more complete and in-depth insight into the mode of action of the compounds.
    [Show full text]
  • Anti-Inflammatory Role of Curcumin in LPS Treated A549 Cells at Global Proteome Level and on Mycobacterial Infection
    Anti-inflammatory Role of Curcumin in LPS Treated A549 cells at Global Proteome level and on Mycobacterial infection. Suchita Singh1,+, Rakesh Arya2,3,+, Rhishikesh R Bargaje1, Mrinal Kumar Das2,4, Subia Akram2, Hossain Md. Faruquee2,5, Rajendra Kumar Behera3, Ranjan Kumar Nanda2,*, Anurag Agrawal1 1Center of Excellence for Translational Research in Asthma and Lung Disease, CSIR- Institute of Genomics and Integrative Biology, New Delhi, 110025, India. 2Translational Health Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, 110067, India. 3School of Life Sciences, Sambalpur University, Jyoti Vihar, Sambalpur, Orissa, 768019, India. 4Department of Respiratory Sciences, #211, Maurice Shock Building, University of Leicester, LE1 9HN 5Department of Biotechnology and Genetic Engineering, Islamic University, Kushtia- 7003, Bangladesh. +Contributed equally for this work. S-1 70 G1 S 60 G2/M 50 40 30 % of cells 20 10 0 CURI LPSI LPSCUR Figure S1: Effect of curcumin and/or LPS treatment on A549 cell viability A549 cells were treated with curcumin (10 µM) and/or LPS or 1 µg/ml for the indicated times and after fixation were stained with propidium iodide and Annexin V-FITC. The DNA contents were determined by flow cytometry to calculate percentage of cells present in each phase of the cell cycle (G1, S and G2/M) using Flowing analysis software. S-2 Figure S2: Total proteins identified in all the three experiments and their distribution betwee curcumin and/or LPS treated conditions. The proteins showing differential expressions (log2 fold change≥2) in these experiments were presented in the venn diagram and certain number of proteins are common in all three experiments.
    [Show full text]
  • The Role of Protein Clearance Mechanisms in Organismal Ageing and Age-Related Diseases
    REVIEW Received 18 Mar 2014 | Accepted 24 Oct 2014 | Published 8 Dec 2014 DOI: 10.1038/ncomms6659 The role of protein clearance mechanisms in organismal ageing and age-related diseases David Vilchez1, Isabel Saez1 & Andrew Dillin2,3 The ability to maintain a functional proteome, or proteostasis, declines during the ageing process. Damaged and misfolded proteins accumulate with age, impairing cell function and tissue homeostasis. The accumulation of damaged proteins contributes to multiple age- related diseases such as Alzheimer’s, Parkinson’s or Huntington’s disease. Damaged proteins are degraded by the ubiquitin–proteasome system or through autophagy-lysosome, key components of the proteostasis network. Modulation of either proteasome activity or autophagic-lysosomal potential extends lifespan and protects organisms from symptoms associated with proteostasis disorders, suggesting that protein clearance mechanisms are directly linked to ageing and age-associated diseases. he integrity of the proteome, or proteostasis, is challenged during the ageing process. Damaged proteins accumulate as a consequence of ageing and may ensue from the Taccumulation of reactive oxygen species and a progressive decline in the ability to maintain a functional proteome1. This demise in proteostasis is considered one of the hallmarks of ageing1 and contributes to multiple age-related diseases such as Alzheimer’s (AD)2, Parkinson’s (PD)3 or Huntington’s disease (HD)4. Proteostasis is maintained by a network of cellular mechanisms that monitors folding, concentration, cellular localization and interactions of proteins from their synthesis through their degradation5. Chaperones assure the proper folding of proteins throughout their life cycle and under stress conditions but their activity declines with age (reviewed in refs 6–10).
    [Show full text]
  • Nuclear Factor-Erythroid-2 Related Transcription Factor-1 (Nrf1) Is Regulated MARK by O-Glcnac Transferase
    Free Radical Biology and Medicine 110 (2017) 196–205 Contents lists available at ScienceDirect Free Radical Biology and Medicine journal homepage: www.elsevier.com/locate/freeradbiomed Original article Nuclear factor-erythroid-2 related transcription factor-1 (Nrf1) is regulated MARK by O-GlcNAc transferase Jeong Woo Hana,1, Joshua L. Valdeza,1, Daniel V. Hoa, Candy S. Leea, Hyun Min Kima, ⁎ Xiaorong Wangb, Lan Huangb,Jefferson Y. Chana, a Department of Laboratory Medicine and Pathology, University of California, Irvine, D440 Medical Sciences, Irvine, CA 92697, USA b Departments of Physiology and Biophysics, University of California, Irvine, D440 Medical Sciences, Irvine, CA 92697, USA ARTICLE INFO ABSTRACT Keywords: The Nrf1 (Nuclear factor E2-related factor 1) transcription factor performs a critical role in regulating cellular Oxidative stress homeostasis. Using a proteomic approach, we identified Host Cell Factor-1 (HCF1), a co-regulator of tran- O-GlcNAcylation scription, and O-GlcNAc transferase (OGT), the enzyme that mediates protein O-GlcNAcylation, as cellular OGT partners of Nrf1a, an isoform of Nrf1. Nrf1a directly interacts with HCF1 through the HCF1 binding motif Transcription factor (HBM), while interaction with OGT is mediated through HCF1. Overexpression of HCF1 and OGT leads to Protein stability increased Nrf1a protein stability. Addition of O-GlcNAc decreases ubiquitination and degradation of Nrf1a. Transcriptional activation by Nrf1a is increased by OGT overexpression and treatment with PUGNAc. Together, these data suggest that OGT can act as a regulator of Nrf1a. 1. Introduction recognized as an essential co-factor for various transcription factors, and it is involved in regulating a plethora of cellular processes including O-GlcNAc transferase (OGT) is a highly conserved enzyme that cell-cycle progression and gene expression [18–21].
    [Show full text]